The breast cancer market is rapidly evolving and presents new commercial opportunities for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio…
DRG Epidemiology’s coverage of endometrial cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
The incidence of gastroesophageal cancer—encompassing gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) adenocarcinoma—continues to rise; however, treatment options remain…
Targeted therapies and various biomarkers (e.g., RAS, BRAF, MSI-H,dMMR) play an important role in the treatment of colorectal cancer. Treatment is becoming increasingly segmented by the side on…
Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga (Johnson &…
Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at…
NASH has the potential to be a large and lucrative therapy market owing to the disease’s prevalence and the lack of approved agents. Patients with NASH are at risk of liver fibrosis,…
Metastatic squamous non-small-cell lung cancer (NSCLC) is an aggressive form of lung cancer with poor survival outcomes. First-line treatment is limited to chemotherapy or immune checkpoint…
Prostate cancer is the most common male urinary tumor and sixth most common male malignant tumor in China. Improved screening tools will result in a significant increase in the diagnosed incidence…
Breast cancer is the most commonly diagnosed cancer among Chinese women. A high incidence and a prolonged treatment duration make the treatment of breast cancer a lucrative commercial opportunity…
The approval two CAR T-cell therapies for relapsed / refractory B-cell hematological malignancies—Novatis’ Kymriah for acute lymphoblastic leukemia (ALL) and large B-cell lymphoma and Kite…
For decades, the treatment landscape of small-cell lung cancer (SCLC) has been dominated by chemotherapy or chemoradiotherapy. In 2018, BristolMyers Squibb’s Opdivo became the first immune…
The approval of Shanghai Henlius Biotech's HLX01—a biosimilar of Roche's Rituxan (rituximab)—in February 2019 marked the beginning of the biosimilars era in China. Since then,…
Immune checkpoint inhibitors have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as a versatile weapon against cancer. The approval of…
Endometrial cancer is the sixth most common cancer in women worldwide. While the majority of patients present with early stage disease at diagnosis, efficacious therapeutic options for advanced or…
